Stockscreener 앱 받기
0.308
2.05%
0.0062
시간 외 거래:
.31
0.002
+0.65%
전일 마감가:
$0.3018
열려 있는:
$0.3068
하루 거래량:
1.29M
Relative Volume:
0.54
시가총액:
$17.23M
수익:
$30.99M
순이익/손실:
$-141.41M
주가수익비율:
-2.0533
EPS:
-0.15
순현금흐름:
$-118.12M
1주 성능:
-7.98%
1개월 성능:
-83.35%
6개월 성능:
-76.84%
1년 성능:
-95.01%
1일 변동 폭
$0.3001
$0.3249
1주일 범위
$0.29
$0.363
52주 변동 폭
$0.2603
$11.26
Marinus Pharmaceuticals Inc Stock (MRNS) Company Profile
명칭
Marinus Pharmaceuticals Inc
전화
484-801-4670
주소
5 RADNOR CORPORATE CENTER SUITE 500, RADNOR, PA
MRNS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| MRNS | 0.308 | 17.23M | 30.99M | -141.41M | -118.12M | -0.15 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Marinus Pharmaceuticals Inc Stock (MRNS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-01-20 | 개시 | RBC Capital Mkts | Outperform |
| 2020-09-30 | 개시 | Truist | Buy |
| 2020-07-01 | 개시 | Cowen | Outperform |
| 2020-07-01 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-09 | 개시 | Craig Hallum | Buy |
| 2019-12-20 | 개시 | Oppenheimer | Outperform |
| 2019-03-05 | 재개 | Jefferies | Buy |
| 2019-02-27 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-02-06 | 개시 | Leerink Partners | Outperform |
| 2018-07-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-03-20 | 개시 | Mizuho | Buy |
| 2018-02-15 | 개시 | H.C. Wainwright | Buy |
| 2017-12-14 | 개시 | Laidlaw | Buy |
| 2016-08-10 | 재확인 | Jefferies | Buy |
| 2016-06-14 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2016-03-08 | 재확인 | Stifel | Buy |
| 2015-12-17 | 개시 | RBC Capital Mkts | Outperform |
| 2015-11-17 | 개시 | Jefferies | Buy |
| 2015-10-30 | 재확인 | Oppenheimer | Outperform |
| 2015-08-05 | 재확인 | Oppenheimer | Outperform |
모두보기
Marinus Pharmaceuticals Inc 주식(MRNS)의 최신 뉴스
Layoff Tracker: Gilead Sciences Will Lay Off 104 Employees at California HQ - BioSpace
MRNS (Marinus Pharmaceuticals) Degree of Operating Leverage : 65.26 (As of Jun. 2024) - GuruFocus.com
Marinus Pharmaceuticals Third Quarter 2024 Earnings: Revenues Disappoint - Simply Wall St
US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest Results - Yahoo Finance
Marinus Pharmaceuticals Lays Off 45% of Employees - BioSpace
Marinus Pharmaceuticals Faces Financial Turmoil Amidst Class Action Lawsuit - TipRanks
Marinus Pharmaceuticals Reports Q3 Growth in ZTALMY Revenue - TipRanks
Marinus Pharmaceuticals' SWOT analysis: navigating challenges in rare epilepsy stock - Investing.com India
Marinus Pharmaceuticals: Q3 Earnings Snapshot - Darien Times
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates - MSN
Marinus Pharmaceuticals Inc Reports Q3 2024 Revenue of $8.54M, G - GuruFocus.com
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results - The Bakersfield Californian
Marinus (MRNS) Q3 Revenue Jumps 56%, Faces Setbacks in Clinical Trials | MRNS Stock News - StockTitan
Marinus Pharmaceuticals Faces Setback with Phase 3 TrustTSC Trial - MSN
Marinus Pharmaceuticals' SWOT analysis: rare epilepsy drug maker's stock faces pivotal moment - Investing.com Canada
Greenlane Holdings to Distribute CURB’s Innovative Inhalation Device: A Game-Changer? - BP Journal
Marinus Pharmaceuticals' SWOT analysis: rare epilepsy drug maker's stock faces pivotal moment By Investing.com - Investing.com South Africa
Marinus downgraded after setback to late-stage trial - MSN
Marinus Pharmaceuticals Hosts Investor and Analyst Day - MSN
TD Cowen Downgrades Marinus Pharmaceuticals (MRNS) - MSN
Marinus tanks after late stage trial for treatment of seizures in TSC fails to meet main goal - MSN
Marinus Pharmaceuticals (MRNS) Halts Ganaxolone Development for TSC After Phase 3 Trial Failure - BP Journal
Marinus Pharmaceuticals Expands Intellectual Property Portfolio with New ZTALMY® Patent - MSN
Marinus Pharmaceuticals price target lowered to $1 from $3 at RBC Capital - TipRanks
Marinus stock downgraded after trial setback (MRNS:NASDAQ) - Seeking Alpha
HC Wainwright Reiterates "Neutral" Rating for Marinus Pharmaceuticals (NASDAQ:MRNS) - MarketBeat
Marinus’ clinical trial of ganaxolone fails to meet primary endpoint - Yahoo! Voices
Marinus Pharma Halts Development After Seizure Drug Fails Trial - Medical Dialogues
JMP Securities Downgrades Marinus Pharmaceuticals (MRNS) - MSN
Marinus halts ganaxolone development after trial setback - Investing.com India
Jefferies cuts Marinus Pharma to hold, slashes target to $0.50 - Investing.com India
Marinus Pharmaceuticals downgraded to Hold from Buy at Jefferies - TipRanks
Jefferies cuts Marinus Pharma to hold, slashes target to $0.50 By Investing.com - Investing.com UK
Marinus halts ganaxolone development after trial setback By Investing.com - Investing.com Australia
Truist cuts Marinus Pharma to hold, drops price target - Investing.com
Truist cuts Marinus Pharma to hold, drops price target By Investing.com - Investing.com UK
Baird cuts Marinus Pharma target to $0.50 on failed study - Investing.com
Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options - AOL
Marinus Pharmaceuticals price target lowered to 50c from $2 at Baird - TipRanks
Marinus Pharmaceuticals downgraded to Market Perform at JMP Securities - TipRanks
Marinus to trim workforce, weigh 'strategic alternatives' after another Ztalmy trial miss sends shares tumbling - FiercePharma
Marinus Pharma stock plunges to 52-week low of $0.52 - Investing.com
Marinus hits record low after discontinuing development of rare disease drug - XM
Marinus Pharma stock plunges to 52-week low of $0.52 By Investing.com - Investing.com Canada
Marinus Pharmaceutical Shares Plumb New Depths After Study Failure - MarketWatch
Marinus Therapeutics plans layoffs, explores strategic alternatives as shares sink - The Business Journals
Marinus Pharmaceuticals Inc (MRNS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):